Clinical trials: Congenital Hepatic Fibrosis
Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University Hospital
Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University Hospital
polycystic kidney disease is aherditary disorder characterized by the formation of numerous fluid filled cysts in the kidneys which can lead to progressive renal impairment PKDencompasses aspectrum of disorders with autosomal…
- Trial name
- NCT06601829
- Testing
- abdominal ultrasound
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Cystic Fibrosis
Outcomes in CF Patients Accessing Their Registry Health Records
A multifactorial, parallel group, randomised control study in cystic fibrosis (CF) patients aged 13-30 years over an 18 month period.
- Trial name
- CFView (NCT03434886)
- Testing
- CFView, CF educational videos
- Volunteers
- 282 people
- Sponsor
- Cystic Fibrosis Registry of Ireland
Cystic Fibrosis
Comparison of Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis
Non-invasive methods of the quantification of fibrosis may help to assess the development of fibrosis at a specific moment of the evolution of the disease, in the order to decide the initiation of treatment with ursodeoxycholic…
- Trial name
- MUCO-FIBRO (NCT02342964)
- Testing
- Measure of hepatic elasticity
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Liver Fibrosis, Alpha-1 Antitrypsin Deficiency
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function.
- Conditions
- Liver Fibrosis, Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD
- Trial name
- NCT01810458
- Testing
- Abdominal ultrasound, History and physical, Intravenous catheter
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of Florida
Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease
ARPKD Database Study
Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive Polycystic Kidney Disease (ARPKD), and other diseases with common features (Joubert syndrome, Bardet Biedl…
- Conditions
- Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease, Joubert Syndrome, Bardet Biedl Syndrome
- Trial name
- ARPKD (NCT01401998)
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- Children's Hospital of Philadelphia
Cancer, COPD
SELF-BREATHE RCT for Chronic Breathlessness
A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)
- Conditions
- Cancer, COPD, Asthma, Bronchiectasis Adult
- Trial name
- NCT04574050
- Testing
- SELF-BREATHE
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- King's College Hospital NHS Trust
Cystic Fibrosis, Cystic Fibrosis Liver Disease
Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients
Diagnosis of hepatic fibrosis is challenging as specific tests for detection of fibrosis in pediatric Cystic Fibrosis associated liver disease (CFALD) have not been developed and existing investigations do not correlate well with…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Liver Disease, Pancreatic Insufficiency Due to Cystic Fibrosis of Pancreas
- Trial name
- CFALD (NCT03264950)
- Testing
- Elastography
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of Manitoba
Liver Cirrhosis, Hemophilia
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
The goal of this observational study is to learn about the changes in coagulation factor VIII and IX levels in patients undergoing liver transplantation to help guide future management of coagulation factor replacement in…
- Conditions
- Liver Cirrhosis, Hemophilia, Hemophilia A, Hemophilia B
- Trial name
- NCT06014320
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Stanford University
Cystic Fibrosis, Cystic Fibrosis Liver Disease
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) triple combination therapy in people with cystic fibrosis initially…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children, Adherence, Medication
- Trial name
- RECOVER (NCT04602468)
- Testing
- Elexacaftor/Tezacaftor/Ivacaftor
- Where
- 7 sites in Ireland, United Kingdom
- Volunteers
- 206 people
- Sponsor
- Royal College of Surgeons, Ireland
Cystic Fibrosis, Pancreatic Insufficiency
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
The specific aims for this study are: 1. To determine if sonographic findings predict the risk of progression of liver disease to cirrhosis by comparing cystic fibrosis subjects with heterogeneous echogenicity pattern on…
- Trial name
- PUSH (NCT01144507)
- Testing
- Abdominal Ultrasound, Sample collection procedures
- Where
- 11 sites in United States, Canada
- Volunteers
- 774 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CDG Ib
Study of ORL-1M (D-mannose) in Patients With CDG-Ib
Study of ORL-1M in Patients With CDG-Ib
- Trial name
- NCT03404869
- Testing
- ORL-1M - D-mannose
- Where
- Turkey (Türkiye)
- Volunteers
- 5 people
- Sponsor
- Orpha Labs
Liver Fibrosis, Beta Thalassemia Major
Elastography vs Iron Regulators in the Diagnosis of Hepatic Fibrosis- Iron Overload in Children With Beta- Thalassemia
The goal of this cross-sectional observational study is to evaluate the accuracy of serum ferritin and serum hepcidin versus non-invasive scores in the diagnosis of liver fibrosis and iron overload in beta- thalassemia children.
- Trial name
- NCT07153926
- Testing
- Serum ferritin, Serum hepcidin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Non Alcoholic Steatohepatitis
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
This study aims to evaluate the possible beneficial effect of empagliflozin versus pioglitazone on non-diabetic patients with non-alcoholic steatohepatitis (NASH). This study will be a randomized, comparative parallel study.
- Trial name
- NCT05605158
- Testing
- Pioglitazone 30mg, Empagliflozin 10 MG
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Tanta University
Cystic Fibrosis, Portal Hypertension
Portal Hypertension and Systemic Endothelial Function
Cystic fibrosis can affect organs other than the lungs. Liver disease affects about 30% of patients: its main manifestation is the development of portal hypertension (PHT).
- Trial name
- ENDOTH-MUCO (NCT02850692)
- Testing
- measure of endothelial function, Blood sample, Hepatic elastography
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hopital Foch
Liver Failure, Kidney Failure
Mesenchymal Stem Cells After Renal or Liver Transplantation
The immune system of a patient can attack the liver or the kidney received from a donor (organ rejection). This can be prevented by treating these patients long-life with immunosuppressive drugs.
- Trial name
- NCT01429038
- Testing
- Mesenchymal Stem Cells
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University of Liege
Beta-Thalassemia, Hepatitis C
Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus
Patients with transfusion dependent Beta Thalassemia suffer from a high incidence of Hepatitis C infection especially in developed countries as Egypt.
- Trial name
- NCT03961828
- Testing
- Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Hepatic Disorders, Intestinal Failure-associated Liver Disease
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
The goal of this observational (diagnostic validation) study is to validate imaging-based biomarkers for assessing liver involvement in pediatric patients with established or suspected liver disease.
- Conditions
- Hepatic Disorders, Intestinal Failure-associated Liver Disease, Cystic Fibrosis Liver Disease, MAFLD
- Trial name
- VALiBi-PED (NCT07202910)
- Where
- Sweden
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Cystic Fibrosis
Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with moderate hepatic impairment and in matched healthy participants.
- Trial name
- NCT05437120
- Testing
- VX-121/TEZ/D-IVA
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated